Buchang Pharma subsidiary expands into biological drug manufacturing

Shandong Buchang Pharmaceuticals announced its controlled subsidiary, Sichuan Luzhou Buchang Bio-Pharmaceutical, obtained approval from the Sichuan Provincial Drug Administration to expand its drug manufacturing license.

The amendment permits the subsidiary to add therapeutic biological products, specifically recombinant human vascular endothelial growth factor receptor 2 full human monoclonal antibody, to its production scope for registration and declaration purposes.

The expansion is expected to optimize the company's production structure and positively impact future operations.